The QbTest Utility in Optimising Treatment for ADHD (QUOTA) study investigates how we might achieve the optimal medication dose for people with ADHD.

Attention-deficit hyperactivity disorder (ADHD) is characterised by symptoms of inattention, hyperactivity and impulsivity. To improve outcomes, the National Institute for Health and Care Excellence ADHD guidelines recommend regular monitoring of symptoms when children commence medication. However, research suggests that routine monitoring rarely happens, and clinicians often rely on subjective information such as reports from parents and teachers to ascertain improvement. These sources can be unreliable and difficult to obtain. The addition of an objective test of attention and activity (QbTest) may improve the objectivity, reliability and speed of clinical decision-making and so reduce the time to identify the optimal medication dose. This study aims to assess the feasibility and acceptability of a QbTest medication management protocol delivered in routine healthcare services for children with ADHD.

For more information, visit https://www.institutemh.org.uk/research/projects-and-studies/current-studies/quota

Read our publication: https://bmjopen.bmj.com/content/8/2/e021104